Today: 18 March 2026
Subscribe
Browse Category

SWX:ROG.SW 18 November 2025 - 20 December 2025

Healthcare Stocks News Today: Drug Pricing Shake-Up, Biotech M&A, IPO Momentum, and 2026 Outlook (Dec. 20, 2025)

Healthcare Stocks News Today: Drug Pricing Shake-Up, Biotech M&A, IPO Momentum, and 2026 Outlook (Dec. 20, 2025)

President Donald Trump and nine major drugmakers announced deals to cut U.S. drug prices for Medicaid and cash-paying patients, with discounts up to 70% off list prices and a three-year tariff reprieve. Shares of several companies rose modestly after the news. Commitments include free Eliquis for Medicaid and steep discounts on diabetes and migraine drugs. The moves reshape investor expectations for healthcare stocks heading into 2026.
20 December 2025
········
MSCI Europe vs World Indices: Performance, Forecasts and Key Drivers (5–7 December 2025)

MSCI Europe vs World Indices: Performance, Forecasts and Key Drivers (5–7 December 2025)

The MSCI Europe Index closed at 2,564.76 on Dec. 5, down 0.25% after a recent rally, but remains up about 12.5% to 15.5% year-to-date in 2025. The index outpaces the MSCI World, which is up roughly 7.7% for the year. European stocks continue to trade at lower valuations, with a 3.03% dividend yield and forward P/E of 14.64. The MSCI Europe Index has 402 constituents and a market cap near $12.85 trillion.
7 December 2025
···········
Swiss Stock Market Today, 26 November 2025: SMI Edges Higher as Sentiment Surges and Insurers Face Tougher Rules

Swiss Stock Market Today, 26 November 2025: SMI Edges Higher as Sentiment Surges and Insurers Face Tougher Rules

The Swiss Market Index closed up 0.07% at 12,781.09 on Wednesday, its highest in about a week, extending a three-day advance. Turnover topped 2.4 million contracts. Investor sentiment jumped after a thaw in Swiss-US trade tensions. Zurich Insurance, Swiss Re, and Swiss Life drew attention after being added to the G20 Financial Stability Board’s insurer resolution list.
26 November 2025
········
Olema Pharmaceuticals (OLMA) Soars Over 200% After Roche Breast Cancer Trial Win — What It Means for Palazestrant and Investors on November 18, 2025

Olema Pharmaceuticals (OLMA) Soars Over 200% After Roche Breast Cancer Trial Win — What It Means for Palazestrant and Investors on November 18, 2025

Olema Pharmaceuticals shares surged as much as 220% in pre-market trading on November 18 after Roche announced a Phase 3 win for its oral SERD giredestrant in early-stage breast cancer. The spike was driven by investor read-through to Olema’s similar drug palazestrant, not new Olema data. Volume hit 13.4 million shares, far above average. Shares later retreated toward the low-$20s during regular trading.
18 November 2025
·····
Swiss Stock Market Today, November 18, 2025: SMI Slips as Roche Soars, ABB, Zurich and ams-Osram Drag the Index

Swiss Stock Market Today, November 18, 2025: SMI Slips as Roche Soars, ABB, Zurich and ams-Osram Drag the Index

The Swiss Market Index fell 0.7% to 12,505 by late morning on November 18, 2025, as global equity declines hit financials and industrials. Roche jumped over 6% to a multi-month high after announcing positive phase III results for its breast cancer drug. ABB, Zurich Insurance, and ams-Osram dropped following investor updates and earnings news. Broader European indices also traded sharply lower.
18 November 2025
····

Stock Market Today

  • Rio2's TSX Graduation and Green Focus Shape Investment Outlook Amid Losses
    March 17, 2026, 10:40 PM EDT. Rio2 Limited reported a net loss of US$13.64 million in 2025 but marked its graduation to the Toronto Stock Exchange (TSX). The company produces gold in Chile and copper, gold, and silver in Peru. Rio2 emphasizes environmental standards beyond compliance to bolster community support and sustainable operations. However, its increased loss and recent equity raises pose risks to near-term value, depending on execution at the Fenix Gold project and Condestable integration. Despite a market pullback easing earlier enthusiasm, shares trade below analyst price targets, reflecting concerns over funding and project risk. Varied fair value estimates, ranging widely, suggest investors should balance multiple views before deciding. Rio2's sustainability focus could aid permits but raises scrutiny on costs, keeping investment sentiment cautious.
Go toTop